Completed
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years
NCT03233217
- Conditions
- Infections, Influenza, Influenza, Human, +5 more
- Locations
-
- Sanofi Pasteur Investigational Site Ōsaka, Japan
- Sanofi Pasteur Investigational Site Tokyo, Japan